January 24, 2023 (Hamilton, ON) – OmniaBio Inc. has expanded its footprint by adding a new process and analytical development lab space at the McMaster University Medical Centre (MUMC). The new facility is now operational.
"This expansion is the latest in a series of exciting milestones for OmniaBio,” says Mitchel Sivilotti, CEO of OmniaBio Inc. “Acquiring additional lab space, ahead of the opening of our commercial facility in 2024, will enable us to better support our growing portfolio of customers, and accelerate their process and analytical development initiatives. We are adding more than 20 highly experienced cell and gene therapy scientists to advance programs from early clinical through to Phase III.”
OmniaBio works as one organization with the teams at CCRM – its parent company. Over the last seven years, CCRM has become recognized as a leader in process and analytical development, and Good Manufacturing Practices (GMP) operations, with expertise in three focused platforms: induced pluripotent stem cells (iPSCs), immunotherapy and lentiviral vectors (LVV). OmniaBio’s expanded lab space will be complementary to the ongoing process and analytical development projects already taking place at CCRM’s site in Toronto, Ontario.
Access the full press release here.
This press release was written and distributed by OmniaBio.
For all enquiries, please contact OmniaBio directly.